Late-breaking post-market study data reinforce clinical procedural success and safety of the acurate neo2™ aortic valve system

Marlborough, mass. , nov. 27, 2022 /prnewswire/ -- boston scientific corporation (nyse:bsx) has announced the first results from the acurate neo2 post market clinical follow-up (pmcf) study evaluating the performance of the acurate neo2 tm aortic valve system.
BSX Ratings Summary
BSX Quant Ranking